VTVT vTv Therapeutics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1641489 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY216,600.0%
TTM net income YoY67.3%
TTM EPS YoY—
Revenue 3-yr CAGR1,499.6%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-29.8%
Net margin-20.8%
FCF margin—
EBITDA margin-29.8%
Returns
ROE-11.0%
ROA-8.6%
ROIC (approx.)—
Asset turnover0.41x
Leverage & solvency
Liabilities / assets11.3%
Debt / equity0.00x
Current ratio11.19x
Interest coverage—
Cash quality & payout
Operating cash flow / net income2.83x
Accruals ratio15.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $1.02M | $0 | $2.02M | $4.00M |
| R&D expense | $17.86M | $11.55M | $13.60M | $12.36M | $13.32M |
| SG&A expense | $14.95M | $13.65M | $11.91M | $12.20M | $12.34M |
| Operating income | -$32.81M | -$24.18M | -$25.50M | -$22.54M | -$21.66M |
| Interest expense | — | $0 | $13,000 | $15,000 | $12,000 |
| Pretax income | -$31.08M | -$22.61M | -$25.97M | -$24.87M | -$17.62M |
| Income tax | $0 | $100,000 | $0 | $200,000 | $115,000 |
| Net income | -$26.97M | -$18.46M | -$20.25M | -$19.16M | -$12.99M |
| EBITDA | -$32.79M | -$24.09M | -$25.41M | -$22.45M | -$21.57M |
| EPS (diluted) | — | — | — | — | — |
| Balance sheet | |||||
| Cash & equivalents | $88.93M | $36.75M | $9.45M | $12.13M | $13.41M |
| Receivables | — | $62,000 | $102,000 | $173,000 | $57,000 |
| Current assets | $89.89M | $38.11M | $10.66M | $27.09M | $15.62M |
| PP&E, net | — | $28,000 | $117,000 | $207,000 | $278,000 |
| Total assets | $89.90M | $38.27M | $11.02M | $33.24M | $25.47M |
| Current liabilities | $6.64M | $5.20M | $10.62M | $7.71M | $8.50M |
| Short-term debt | — | — | — | — | $256,000 |
| Total liabilities | $25.46M | $23.96M | $29.57M | $27.40M | $10.25M |
| Shareholders' equity | $64.44M | $12.20M | -$24.68M | -$10.74M | -$9.74M |
| Cash flow statement | |||||
| Operating cash flow | -$25.25M | -$25.31M | -$19.08M | -$16.02M | -$19.31M |
| Capital expenditure | — | $0 | $0 | $21,000 | $0 |
| Free cash flow | — | -$25.31M | -$19.08M | -$16.04M | -$19.31M |
| Investing cash flow | $0 | $0 | $4.40M | -$21,000 | $0 |
| Financing cash flow | $77.44M | $52.61M | $12.00M | $14.75M | $26.98M |
| Depreciation & amortization | $16,000 | $89,000 | $90,000 | $92,000 | $89,000 |
| Stock-based compensation | $3.77M | $2.76M | $1.58M | $1.27M | $2.36M |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.